The orphan disease drug developer's latest round was led by Novo while Asahi Kasei and Chiesi Ventures also participated, taking its overall funding to $46m.

Novo led a $33m series B round for US-based replacement therapy developer Glycomine on Wednesday that included fellow pharmaceutical firms Asahi Kasei Pharma¬†and Chiesi Group. Venture capital firm Mission Bay Capital and life sciences investment firm Sanderling Ventures also took part in the round, while Chiesi invested through corporate venturing vehicle Chiesi Ventures. Founded in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.